Gilead (GILD) to Showcase New Cancer Therapy Data
Gilead Sciences said it and its subsidiary Kite will present 25+ cancer abstracts at the 2026 ASCO meeting (May 29–June 2) and EHA Congress (June 11–14). ASCO includes new Phase 3 Trodelvy first-line metastatic triple-negative breast cancer analyses on long-term progression-free survival, plus anito-cel manufacturing consistency data. EHA will cover durability and safety for KITE-753. Separately, Gilead reported Phase 3 interim data that Livdelzi achieved high, sustained ALP normalization in pri
Multiple oncology and liver-disease clinical updates increase near-term catalyst density ahead of ASCO/EHA and support continued valuation for pipeline progress.
Gilead will present new Phase 3 Trodelvy and CAR-T (anito-cel, KITE-753) data at ASCO/EHA, plus Livdelzi Phase 3 interim ALP normalization results.
Moderate positive drift possible into conference windows if investors view the data as strengthening efficacy/durability signals.
Background
The piece frames Gilead’s upcoming ASCO and EHA congress presentations and adds a separate Phase 3 interim update for Livdelzi in primary biliary cholangitis.
Why it matters
For trading, the key is catalyst timing (ASCO/EHA) plus the specific Phase 3 readouts cited (Trodelvy first-line mTNBC long-term PFS; anito-cel manufacturing consistency; KITE-753 durability/safety; Livdelzi ALP normalization over two years).
Market relevance
A multi-program clinical catalyst calendar (ASCO/EHA) plus a Phase 3 interim efficacy/tolerability datapoint can support bullish positioning into the conference period.
Market effects
Reinforces investor appetite for late-stage oncology and CAR-T durability/manufacturing quality narratives across large-cap pharma/biotech.
Primarily US-driven sentiment as ASCO/EHA are US-centric catalysts, with potential global read-through to European biotech conferences.
Could influence broader global expectations for CAR-T durability and liver-marker normalization endpoints in PBC.
Alternative perspectives
Qualitative “high/sustained normalization” and “well-tolerated” may already be partly expected; without effect-size numbers, market may discount the incremental signal.
Conference presentations can face skepticism if endpoints are surrogate/secondary or if prior trial expectations were already high; also, manufacturing consistency disclosures may not translate into commercial scalability without cost/yield details.
Key entities
- companyGilead Sciences
Subject of the article; provides multiple late-stage oncology and PBC clinical updates and conference plans.
- subsidiaryKite
Will present manufacturing consistency data for anito-cel and durability/safety results for KITE-753.
